Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Physicians Research Collaboration

Neither a doctor nor a teaching hospital

Research payments

$1,091,841

192 payments

Through program year 2025, Physicians Research Collaboration is reported as receiving $1,091,841 in research payments, across 192 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $214,390 3
2024 Research $45,023 2
2023 Research $26,709 4
2022 Research $45,660 9
2021 Research $418,977 104
2020 Research $334,689 62
2019 Research $6,393 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $640,038 157 payments
  2. Eli Lilly and Company $448,266 28 payments
  3. AbbVie, Inc. $3,537 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $304,065 54 payments
  2. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $204,949 3 payments
  3. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $175,144 55 payments
  4. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $160,829 48 payments
  5. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $158,785 5 payments
  6. A Phase 2 Study to Evaluate the Efficacy and Safety of Ly3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis $29,038 3 payments
  7. A Randomized Active-Controlled Parallel-Group Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $26,232 1 payment
  8. A Multicenter Long-Term Extension Study of 104 Weeks Including A Double Blind Placebo Controlled 40 Week Randomized Withdrawal Retreatment Period to Evaluate the Maintenance of Treatment Effect of Ixekizumab Ly2439821 in Patients With Axial Spondyloarthritis $22,317 4 payments
  9. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $4,266 2 payments
  10. A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis $1,806 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record